FDA Approves Autolus's AUCATZYL for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Autolus Therapeutics has achieved a significant milestone with FDA approval for AUCATZYL (obecabtagene autoleucel), a next-generation CAR T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). This approval, granted based on results from the FELIX clinical trial, highlights the therapy's efficacy, with a 63% overall complete remission rate in the efficacy-evaluable patient cohort. Notably, AUCATZYL also demonstrated a favorable safety profile with low rates of severe Cytokine Release Syndrome and Immune Effector Cell-Associated...
